loading page

Pan-lysyl oxidase inhibitor PXS-5505 ameliorates multiple-organ fibrosis by inhibiting collagen crosslinks in rodent models of systemic sclerosis
  • +3
  • Yimin Yao,
  • Alison Findlay,
  • Jessica Stolp,
  • Benjamin Rayner,
  • Kjetil Ask,
  • Wolfgang Jarolimek
Yimin Yao
Pharmaxis Ltd
Author Profile
Alison Findlay
Pharmaxis Ltd
Author Profile
Jessica Stolp
Pharmaxis Ltd
Author Profile
Benjamin Rayner
Childrens Cancer Institute of Australia for Medical Research
Author Profile
Kjetil Ask
McMaster University
Author Profile
Wolfgang Jarolimek
Pharmaxis Ltd
Author Profile


Background/Purpose: Systemic sclerosis (SSc) is characterised by progressive multiple-organ fibrosis leading to morbidity and mortality. Lysyl oxidases play a vital role in the cross-linking of collagens and subsequent build-up of fibrosis in the extracellular matrix. As such, their inhibition provides a novel treatment paradigm for SSc. Experimental Approach: Lysyl oxidases are upregulated in preclinical models of fibrosis in skin, lung, heart, kidney and liver. A novel small molecule pan-lysyl oxidase inhibitor, PXS-5505, currently in clinical development for bone fibrosis treatment was evaluated in in vivo rodent models resembling the fibrotic conditions in SSc. Key Results: Both lysyl oxidase and lysyl oxidase-like 2 (LOXL2) expression was elevated in the skin and lung of SSc patients. Once-a-day oral application of PXS-5505 inhibited lysyl oxidase activity in the skin and LOXL2 activity in the lung. PXS-5505 exhibited anti-fibrotic effects in the SSc skin mouse model, reducing dermal thickness and α-smooth muscle actin compared to the disease controls. Similarly, in the bleomycin-induced mouse lung model, PXS-5505 reduced tissue fibrosis toward normal levels. The anti-fibrotic efficacy of PXS-5505 in the bleomycin exposed lungs was mediated by its ability to normalise collagen/elastin crosslink formation, a direct consequence of lysyl oxidase inhibition. PXS-5505 also reduced area of fibrosis in rodent models of the ischaemia-reperfusion heart, the unilateral ureteral obstruction kidney and the CCl4-induced fibrotic liver. Conclusion/Implication: PXS-5505 consistently demonstrates potent anti-fibrotic efficacy in multiple models of organ fibrosis relevant to the pathogenesis of SSc, suggesting that it may be efficacious as a novel approach for treating SSc.

Peer review status:UNDER REVIEW

19 Nov 2021Submitted to British Journal of Pharmacology
23 Nov 2021Assigned to Editor
23 Nov 2021Submission Checks Completed
02 Dec 2021Reviewer(s) Assigned